HAE HAEMONETICS CORP MASS revenue, earnings and financials

For the quarter ended June 27, 2026, HAEMONETICS CORP MASS reported revenue of $339M (up 5.6% from a year earlier), net income of $33.0M and diluted EPS of $0.72; over the last four quarters revenue was $1.35B and net income −$924K; for the fiscal year ended March 2026 revenue was $1.33B, down 2.0% on the year before.

HAE annual revenue and earnings

• Fiscal year ended Mar 2026: revenue $1.33B, gross profit $788M, operating income $157M, net income $97.3K (margin 0.0%), EPS $2.05
• Fiscal year ended Mar 2025: revenue $1.36B, gross profit $749M, operating income $222M, net income $168K (margin 0.0%), EPS $3.31
• Fiscal year ended Mar 2024: revenue $1.31B, gross profit $692M, operating income $165M, net income $118M (margin 9.0%), EPS $2.29
• Fiscal year ended Apr 2023: revenue $1.17B, gross profit $615M, operating income $156M, net income $115M (margin 9.9%), EPS $2.24
• Fiscal year ended Apr 2022: revenue $993M, gross profit $506M, operating income $80.8M, net income $43.4M (margin 4.4%), EPS $0.84

HAE quarterly revenue and earnings

• Quarter ended Jun 27, 2026: revenue $339M (up 5.6% year over year), net income $33.0M, EPS $0.72
• Quarter ended Mar 28, 2026 (from the annual report): revenue $346M (up 4.8% year over year), net income −$117M, EPS −$0.41
• Quarter ended Dec 27, 2025: revenue $339M (down 2.7% year over year), net income $44.7M, EPS $0.95
• Quarter ended Sep 27, 2025: revenue $327M (down 5.3% year over year), net income $38.7M, EPS $0.81
• Quarter ended Jun 28, 2025: revenue $321M (down 4.4% year over year), net income $34.0M, EPS $0.70
• Quarter ended Mar 29, 2025 (from the annual report): revenue $331M (down 3.7% year over year), net income −$110M, EPS $1.17
• Quarter ended Dec 28, 2024: revenue $349M (up 3.7% year over year), net income $37.5M, EPS $0.74
• Quarter ended Sep 28, 2024: revenue $346M (up 8.6% year over year), net income $33.8M, EPS $0.66
• Quarter ended Jun 29, 2024: revenue $336M (up 8.0% year over year), net income $38.4M, EPS $0.74
• Quarter ended Mar 30, 2024 (from the annual report): revenue $343M (up 12.8% year over year), net income $20.4M, EPS $0.40
• Quarter ended Dec 30, 2023: revenue $336M (up 10.1% year over year), net income $31.2M, EPS $0.61
• Quarter ended Sep 30, 2023: revenue $318M (up 7.0% year over year), net income $24.9M, EPS $0.48
• Quarter ended Jul 1, 2023: revenue $311M (up 19.1% year over year), net income $41.0M, EPS $0.80
• Quarter ended Apr 1, 2023 (from the annual report): revenue $304M (up 14.9% year over year), net income $29.4M, EPS $0.58
• Quarter ended Dec 31, 2022: revenue $305M (up 17.5% year over year), net income $32.9M, EPS $0.64
• Quarter ended Oct 1, 2022: revenue $297M (up 24.0% year over year), net income $33.2M, EPS $0.64
• Quarter ended Jul 2, 2022: revenue $261M (up 14.4% year over year), net income $19.9M, EPS $0.38
• Quarter ended Apr 2, 2022 (from the annual report): revenue $265M (up 17.8% year over year), net income $9.74M, EPS $0.19
• Quarter ended Jan 1, 2022: revenue $260M, net income $23.2M, EPS $0.45
• Quarter ended Oct 2, 2021: revenue $240M, net income $14.9M, EPS $0.29

HAE cash flow, buybacks and dividends

• Fiscal year ended Mar 2026: operating cash flow $293M, share buybacks $175M
• Fiscal year ended Mar 2025: operating cash flow $182M, share buybacks $225M
• Fiscal year ended Mar 2024: operating cash flow $182M, share buybacks $0
• Fiscal year ended Apr 2023: operating cash flow $273M, share buybacks $75.0M
• Fiscal year ended Apr 2022: operating cash flow $172M, share buybacks $0

HAE balance sheet

• Jun 27, 2026: cash $223M, total assets $2.37B, total liabilities n/a, shareholders' equity $837M, long-term debt $1.17B
• Mar 28, 2026: cash $245M, total assets $2.40B, total liabilities n/a, shareholders' equity $796M, long-term debt $1.22B
• Dec 27, 2025: cash $363M, total assets $2.49B, total liabilities n/a, shareholders' equity $911M, long-term debt $920M
• Sep 27, 2025: cash $296M, total assets $2.44B, total liabilities n/a, shareholders' equity $849M, long-term debt $920M
• Jun 28, 2025: cash $293M, total assets $2.46B, total liabilities n/a, shareholders' equity $882M, long-term debt $921M
• Mar 29, 2025: cash $307M, total assets $2.45B, total liabilities n/a, shareholders' equity $821M, long-term debt $921M
• Dec 28, 2024: cash $321M, total assets $2.53B, total liabilities n/a, shareholders' equity $907M, long-term debt $1.22B
• Sep 28, 2024: cash $299M, total assets $2.53B, total liabilities n/a, shareholders' equity $879M, long-term debt $1.22B

What is HAE's revenue?

HAEMONETICS CORP MASS reported $1.35B of revenue over its last four quarters, through June 27, 2026.

Is HAE profitable?

No. HAEMONETICS CORP MASS lost $924K over the last four quarters.

What is HAE's EPS?

Diluted earnings per share over the last four quarters were $2.07; $0.72 in the latest quarter.

HAE ownership and insider trades · All stocks